


GRANTED**(IN370943)**

Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics



NEED

Ocular infections caused by Gram-positive and Gram-negative bacteria pose significant health risks, often leading to vision impairment. Current treatments fail to effectively target the infection site while maintaining prolonged efficacy.

TECHNOLOGY OVERVIEW

This innovation provides a mucoadhesive ophthalmic drug delivery system containing a fluoroquinolone antibiotic, chitosan, and other polymers for controlled release. It ensures better ocular absorption and effective treatment for various eye infections like conjunctivitis and keratitis.

TECHNOLOGY KEY FEATURES

Mucoadhesive system, fluoroquinolone antibiotics, controlled release, chitosan, polyvinyl alcohol, polyvinylpyrrolidone, enhanced ocular absorption, treatment for bacterial ocular infections, prolonged efficacy.

[Read more here](#)

MARKET ANALYSIS

The global ophthalmic drug market is projected to grow at a CAGR of 6.5%, reaching \$18 billion by 2033, driven by rising eye infections and demand for effective treatments. [Source: Market Research Future, 2023]

Target Industries

Pharmaceuticals, Healthcare, Drug Delivery Systems, Pharmaceutical manufacturers, medical device developers, healthcare providers, R&D for ocular drug delivery.

AT A GLANCE

- SDG 3 (Good Health and Well-Being), SDG 9 (Industry, Innovation, and Infrastructure)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913